Clinical Scorecard: Interleukin-34-Driven Interactions Between Fibroblast-Like Synoviocytes and Macrophages Promote Bone Erosion via RANKL-Dependent Osteoclast Formation in Rheumatoid Arthritis
At a Glance
Category
Detail
Condition
Key Mechanisms
IL-34-mediated crosstalk between fibroblast-like synoviocytes and macrophages promotes osteoclastogenesis through RANKL. [Needs source attribution]
Target Population
Care Setting
Key Highlights
IL-34 levels correlate with RA severity and bone erosion. [Needs source attribution]
IL-34 promotes proliferation and migration of fibroblast-like synoviocytes. [Needs source attribution]
Macrophage recruitment and M1 polarization are enhanced by IL-34. [Needs source attribution]
RANKL production and osteoclast differentiation are increased in the presence of IL-34. [Needs source attribution]
IL-34 blockade reduces RA severity and bone erosion in animal models. [Remove unless sourced]
Guideline-Based Recommendations
Diagnosis
Management
Consider IL-34 blockade as a therapeutic strategy to alleviate RA symptoms. [Remove unless sourced]
Monitoring & Follow-up
Risks
Patient & Prescribing Data
IL-34 neutralizing antibodies may mitigate synovial hyperplasia and inflammation. [Needs source attribution]
Clinical Best Practices
Incorporate IL-34 level assessments in routine RA evaluations. [Needs source attribution]
